Plasma insulin-like growth factor I levels are higher in depressive and anxiety disorders, but lower in antidepressant medication users

Psychoneuroendocrinology

Volumn 68, Issue , 2016, Pages 148-155

  Bot, Mariska ^a   Milaneschi, Yuri ^a   Penninx, Brenda W J H ^a   Drent, Madeleine L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antidepressant medication; Anxiety disorders; Cohort; Depressive disorders; Insulin like growth factor I; Neurotrophic factor

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE MALEATE; PAROXETINE; SERTRALINE; SOMATOMEDIN C; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGE; AGED; ANXIETY DISORDER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REMISSION; ANXIETY DISORDERS; BLOOD; DEPRESSIVE DISORDER, MAJOR; METABOLISM; PSYCHOLOGY;

ADULT; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; CROSS-SECTIONAL STUDIES; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; NETHERLANDS;

EID: 84960415801     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2016.02.028     Document Type: Article

References (52)

1. Aberg M.A., Aberg N.D., Hedbacker H., Oscarsson J., Eriksson P.S. Peripheral infusion of IGF-I selectively induces neurogenesis in the adult rat hippocampus. J. Neurosci. 2000, 20:2896-2903.
2. Aleman A., Torres-Aleman I. Circulating insulin-like growth factor I and cognitive function: neuromodulation throughout the lifespan. Prog. Neurobiol. 2009, 89:256-265.
3. Armstrong C.S., Wuarin L., Ishii D.N. Uptake of circulating insulin-like growth factor-I into the cerebrospinal fluid of normal and diabetic rats and normalization of IGF-II mRNA content in diabetic rat brain. J. Neurosci. Res. 2000, 59:649-660.
4. Arwert L.I., Deijen J.B., Drent M.L. The relation between insulin-like growth factor I levels and cognition in healthy elderly: a meta-analysis. Growth Horm. IGF Res. 2005, 15:416-422.
5. Auer A., Sievers C., Schneider H.J., Stalla G.K. The GH/IGF-1-axis in psychopathological functions. TOEJ 2012, 6:62-67.
6. Beck A.T., Brown G., Epstein N., Steer R.A. An inventory for measuring clinical anxiety ? psychometric properties. J. Consult. Clin. Psych. 1988, 56:893-897.
7. Bot M., Chan M.K., Jansen R., Lamers F., Vogelzangs N., Steiner J., et al. Serum proteomic profiling of major depressive disorder. Transl. Psychiatry 2015, 5:e599.
8. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Erlbaum Associates, Hillsdale, NJ.
9. Craig C.L., Marshall A.L., Sjostrom M., Bauman A.E., Booth M.L., Ainsworth B.E., et al. International physical activity questionnaire: 12-country reliability and validity. Med. Sci. Sports 2003, 35:1381-1395.
10. Deuschle M., Blum W.F., Strasburger C.J., Schweiger U., Weber B., Korner A., et al. Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology 1997, 22:493-503.
11. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 1997, 54:597-606.
12. Duman C.H., Schlesinger L., Terwilliger R., Russell D.S., Newton S.S., Duman R.S. Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise. Behav. Brain Res. 2009, 198:366-371.
13. Duman R.S. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromol. Med. 2004, 5:11-25.
14. Eisch A.J., Petrik D. Depression and hippocampal neurogenesis: a road to remission?. Science 2012, 338:72-75.
15. Emeny R.T., Bidlingmaier M., Lacruz M.E., Linkohr B., Peters A., Reincke M., et al. Mind over hormones: sex differences in associations of well-being with IGF-I, IGFBP-3 and physical activity in the KORA-Age study. Exp. Gerontol. 2014, 59:58-64.
16. Fernandez A.M., Torres-Aleman I. The many faces of insulin-like peptide signalling in the brain. Nat. Rev. Neurosci. 2012, 13:225-239.
17. Franz B., Buysse D.J., Cherry C.R., Gray N.S., Grochocinski V.J., Frank E., et al. Insulin-like growth factor 1 and growth hormone binding protein in depression: a preliminary communication. J. Psychiatr. Res. 1999, 33:121-127.
18. Frystyk J. Free insulin-like growth factors-measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm. IGF Res. 2004, 14:337-375.
19. Giovannucci E., Pollak M., Liu Y., Platz E.A., Majeed N., Rimm E.B., et al. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol. Biomarkers Prev. 2003, 12:84-89.
20. Hoshaw B.A., Malberg J.E., Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res. 2005, 1037:204-208.
21. Kessler R.C., Wang P.S. The descriptive epidemiology of commonly occurring mental disorders in the United States. Annu. Rev. Public Health 2008, 29:115-129.
22. Kopczak A., Stalla G.K., Uhr M., Lucae S., Hennings J., Ising M., et al. IGF-I in major depression and antidepressant treatment response. Eur. Neuropsychopharmacol. 2015, 25:864-872.
23. Lamers F., van Oppen P., Comijs H.C., Smit J.H., Spinhoven P., van Balkom A.J.L.M., et al. Comorbidity patterns of anxiety and depressive disorders in a large Cohort Study: the Netherlands Study of Depression and Anxiety (NESDA). J. Clin. Psychiatry 2011, 72:341-348.
24. Lin F., Suhr J., Diebold S., Heffner K.L. Associations between depressive symptoms and memory deficits vary as a function of insulin-like growth factor (IGF-1) levels in healthy older adults. Psychoneuroendocrinology 2014, 42:118-123.
25. Malberg J.E., Platt B., Rizzo S.J., Ring R.H., Lucki I., Schechter L.E., et al. Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology 2007, 32:2360-2368.
26. Mason C., Xiao L., Duggan C., Imayama I., Foster-Schubert K.E., Kong A., et al. Effects of dietary weight loss and exercise on insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in postmenopausal women: a randomized controlled trial. Cancer Epidemiol. Biomarkers Prev. 2013, 22:1457-1463.
27. Meesters P., Kerkhofs M., Charles G., Decoster C., Vanderelst M., Mendlewicz J. Growth hormone release after desipramine in depressive illness. Eur. Arch. Psychiatry Neurol. Sci. 1985, 235:140-142.
28. Miller A.H., Maletic V.F., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
29. Molendijk M.L., de Kloet E.R. Immobility in the forced swim test is adaptive and does not reflect depression. Psychoneuroendocrinology 2015, 62:389-391.
30. Molendijk M.L., Spinhoven P., Polak M., Bus B.A., Penninx B.W., Elzinga B.M. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N = 9484). Mol. Psychiatry 2014, 19:791-800.
31. O'Connor J.C., McCusker R.H., Strle K., Johnson R.W., Dantzer R., Kelley K.W. Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology. Cell. Immunol. 2008, 252:91-110.
32. O'Flynn K., O'Keane V., Dinan T.G. Effect of fluoxetine on noradrenergic mediated growth hormone release: a double blind controlled study. J. Psychopharmacol. 1992, 6:119.
33. O'Kusky J.R., Ye P., D'Ercole A.J. Insulin-like growth factor-I promotes neurogenesis and synaptogenesis in the hippocampal dentate gyrus during postnatal development. J. Neurosci. 2000, 20:8435-8442.
34. Pan W., Kastin A.J. Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. Neuroendocrinology 2000, 72:171-178.
35. B.W.J.H Penninx, Beekman A.T.F., Smit J.H., Zitman F.G., Nolen W.A., Spinhoven P., et al. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. Int. J. Method Psychiatr. 2008, 17:121-140.
36. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008, 33:88-109.
37. Rosen T., Wiren L.F., Wilhelmsen L.F., Wiklund I.F., Bengtsson B.A. Decreased psychological well-being in adult patients with growth hormone deficiency. Clin. Endocrinol. (Oxf.) 1994, 40:111-116.
38. Rozing M.P., Westendorp R.G., Frolich M., de Craen A.J., Beekman M., Heijmans B.T., et al. Human insulin/IGF-1 and familial longevity at middle age. Aging (Albany, NY) 2009, 1:714-722.
39. Rush A.J., Gullion C.M., Basco M.R., Jarrett R.B., Trivedi M.H. The inventory of depressive symptomatology (IDS): psychometric properties. Psychol. Med. 1996, 26:477-486.
40. Schilling C., Blum W.F., Heuser I., Paslakis G., Wudy S.A., Deuschle M. Treatment with antidepressants increases insulin-like growth factor-I in cerebrospinal fluid. J. Clin. Psychopharmacol. 2011, 31:390-392.
41. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 2008, 64:527-532.
42. Sievers C., Dimopoulou C., Pfister H., Lieb R., Steffin B., Roemmler J., et al. Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients. Clin. Endocrinol. (Oxf.) 2009, 71:691-701.
43. Sievers C., Auer M.K., Klotsche J., Athanasoulia A.P., Schneider H.J., Nauck M., et al. IGF-I levels and depressive disorders: results from the Study of Health in Pomerania (SHIP). Eur. Neuropsychopharmacol. 2014, 24:890-896.
44. Stetler C., Miller G.E. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom. Med. 2011, 73:114-126.
45. Szczesny E., Slusarczyk J.F., Glombik K.F., Budziszewska B.F., Kubera M.F., Lason W.F., et al. Possible contribution of IGF-1 to depressive disorder. Pharmacol. Rep. 2013, 65:1622-1631.
46. Torres-Aleman I. Serum growth factors and neuroprotective surveillance: focus on IGF-1. Mol. Neurobiol. 2000, 21:153-160.
47. Trivedi M.H., Greer T.L. Cognitive dysfunction in unipolar depression: implications for treatment. J. Affect. Disord. 2014, 152-154:19-27.
48. Weber-Hamann B., Blum W.F., Kratzsch J.F., Gilles M.F., Heuser I.F., Deuschle M. Insulin-like growth factor-I (IGF-I) serum concentrations in depressed patients: relationship to saliva cortisol and changes during antidepressant treatment. Pharmacopsychiatry 2009, 42:23-28.
49. Wilkins J.N., Spar J.E., Carlson H.E. Desipramine increases circulating growth hormone in elderly depressed patients: a pilot study. Psychoneuroendocrinology 1989, 14:195-202.
50. Wittchen H.U. Reliability and validity studies of the who composite international diagnostic interview (Cidi)-a critical-review. J. Psychiatr. Res. 1994, 28:57-84.
51. World Health Organization Collaboration Centre for Drug Statistics Methodology Anatomical Therapeutic Chemical (ATC) Classification System 2007, World Health Organization, Oslo, Norway.
52. van Varsseveld N.C., van Bunderen C.C., Sohl E., Comijs H.C., Penninx B.W., Lips P., et al. Serum insulin-like growth factor 1 and late-life depression: a population-based study. Psychoneuroendocrinology 2015, 54:31-40.